Lucisel Capsules

Introduction of  Lucisel (Selpercatinib) Capsule

• Active Ingredient: Selpercatinib – a selective RET kinase inhibitor, designed to target cancers driven by RET gene fusions or mutations.
  lucius-pharmaceuticals.comgoldtreepharmaceuticals.com

• Indications:

  • RET fusion-positive Non-Small Cell Lung Cancer (NSCLC), especially metastatic cases

  • RET-positive thyroid cancers, including medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma
    lucius-pharmaceuticals.comgoldtreepharmaceuticals.com

• Mechanism of Action of Lucisel Capsule

  • Binds specifically to the RET receptor tyrosine kinase

  • Blocks abnormal signaling caused by RET mutations or fusions

  • Slows tumor growth, promotes cancer cell death, and offers potential efficacy in CNS (central nervous system) metastases
    lucius-pharmaceuticals.com

• Benefits of Lucisel Capsule

  • Precision-targeted therapy with minimal effects on healthy cells

  • Demonstrated high response rates and durable effects in clinical trials

  • Orally administered, making it more convenient compared to intravenous chemotherapy
    

Key Clinical Highlights of Lucisel Capsule

• Clinical Efficacy of Lucisel Capsule

  • Response rate (ORR) for RET fusion–positive NSCLC is around 68%

  • Many patients experience prolonged responses, often lasting over a year

  • Shows improvements in overall survival (OS) and progression-free survival (PFS) compared to standard treatments
    

• Side Effects:

  • Common: fatigue, hypertension, diarrhea, nausea, elevated liver enzymes

  • Requires monitoring of blood pressure and liver function